Recursion Pharmaceuticals, Inc. (RXRX) shares tumbled 5% in pre-market trading on Wednesday following the release of disappointing third-quarter results and the announcement of a significant leadership change.

The biotech company reported a staggering miss on its Q3 revenue, posting just $4.983 million compared to analysts' expectations of $17 million. This substantial shortfall was accompanied by concerning financial figures, including an operating loss of $172.202 million and a net loss of $162.253 million for the quarter. These results underscore the ongoing challenges faced by Recursion in its pursuit of AI-assisted drug discovery and development.

Adding to investor uncertainty, Recursion announced a major leadership transition. Effective January 1, 2026, current Chief R&D and Commercial Officer Najat Khan, Ph.D., will succeed co-founder Chris Gibson, Ph.D., as CEO and President. Gibson will transition to the role of Chairman of the Board and serve as an interim Executive Advisor. While this change aims to drive the next phase of growth for the company, it may be contributing to short-term market jitters as investors assess the potential impact on Recursion's future direction and performance.